ACCURAY INC
ARAYNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $458.5M | $446.6M | $447.6M | $429.9M | $102.6M | $99.5M |
| Operating income | $7.8M | $504,000 | $2.4M | $8.1M | $22.2M | $12.5M |
| Net income | −$1.6M | −$15.5M | −$9.3M | −$5.3M | −$390,000 | $2.6M |
| Total assets | $470.2M | $468.6M | $479.2M | $472.8M | $480.1M | $490.9M |
| Total liabilities | $389.1M | $423.5M | $425.6M | $419.7M | $411.3M | $427.3M |
| Equity | $81.2M | $45.1M | $53.7M | $53.2M | $68.8M | $63.6M |
| EPS (diluted) | $-0.02 | $-0.16 | $-0.10 | $-0.06 | $0.00 | $0.04 |
| Shares out. | 112.7M | 100.3M | 96.6M | 93.5M | 90.8M | 91.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 1.7%
- Net margin
- −0.3%
- Return on equity
- −2.0%
- Return on assets
- −0.3%
- Return on capital (ROCE)
- 2.8%
- Liabilities / assets
- 82.7%
- Debt / equity
- 4.79×
- Book value / share
- $0.72
- Revenue growth (YoY)
- 2.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.53distress
- Accruals / assets
- −0.9%clean
- Beneish M-Score
- -2.55normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 4 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 9, 2026
- NT 10-Kmissed a reporting deadline ↗Sep 16, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Chalke SandeepOfficer — SVP, Chief Commercial Officer | Mar 31, 2026 | Tax withholding | 40,000 | $0.39 |
| Peralta LeonelOfficer — SVP, Chief Operations Officer | Feb 28, 2026 | Option exercise | 83,723 | $0.00 |
| Mayer Steven FDirector | Feb 20, 2026 | Buy | 54,875 | $0.56 |
| Mayer Steven FDirector | Feb 18, 2026 | Buy | 126,125 | $0.53 |
| Scott Byron CDirector | Dec 31, 2025 | Option exercise | 9,433 | $0.00 |
| Pervaiz AliOfficer — SVP Chief Financial Officer | Nov 29, 2025 | Option exercise | 44,025 | $0.00 |
| Chalke SandeepOfficer — SVP, Chief Commercial Officer | Nov 29, 2025 | Option exercise | 50,314 | $0.00 |
| Galbato ChanDirector | Nov 28, 2025 | Grant | 50,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.6M | 1.2 | -4.3% |
| Apr 30, 2026 | 6.9M | 7.6 | -12.8% |
| Apr 15, 2026 | 7.9M | 5.0 | +3.9% |
| Mar 31, 2026 | 7.6M | 5.1 | +15.3% |
| Mar 13, 2026 | 6.6M | 4.3 | +20.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 6, 2026
- Director / officer changeApr 28, 2026
- Entered a material agreementApr 7, 2026
- Regulation FD disclosureApr 6, 2026
- Director / officer changeMar 19, 2026
- Regulation FD disclosureFeb 17, 2026
- Prior financials not reliable (restatement)Feb 9, 2026
- Delisting / listing-standard noticeFeb 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4PRIMARY DOCUMENTMay 29, 2026
- SDFORM SDMay 29, 2026
- S-8FORM S-8May 29, 2026
- SCHEDULE 13D/AMay 22, 2026
- 4OWNERSHIP DOCUMENTMay 21, 2026
- 10-QFORM 10-QMay 6, 2026
- 8-KFORM 8-KMay 6, 2026
- 8-KFORM 8-KApr 28, 2026
- SCHEDULE 13D/AApr 17, 2026
- 3OWNERSHIP DOCUMENTApr 17, 2026
- 3PRIMARY DOCUMENTApr 10, 2026
- 8-KFORM 8-KApr 7, 2026
- 8-KFORM 8-KApr 6, 2026
- 4PRIMARY DOCUMENTApr 1, 2026
- SCHEDULE 13G/AMar 26, 2026